Fundraising Fox
Axim Biotechnologies
OTC: AXIMNew York, US · Founded 2018 · Nevada corporation
Find your way into Axim Biotechnologies
Sign up to see every warm intro you have to Axim Biotechnologies
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Axim Biotechnologies team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
AXIM Biotechnologies is a research and development company that develops rapid point-of-care diagnostic tests for ophthalmological conditions, targeting ocular biomarkers linked to aqueous deficient dry eye disease and allergic conjunctivitis. Its tests are designed to help eye-care physicians detect and quantify these biomarkers.
Founders & leadership
Axim Biotechnologies was founded in 2018 by Dr. Philip A Van Damme, Dr. George Anastassov, and Catalina Valencia.
Reported raises · per SEC filings
Form D private placements$1.2M disclosed across 3 of 4 rounds · 2014–2020
▶$500KraisedJun 2020 · 1 investors · BiotechnologyRule 506(b)
- TIMOTHY R SCOTTDirector
- MAURICO BELLORADirector
- ROBERT MALASEKExecutive Officer
- ROBERT L CUNNINGHAMDirector
- JOHN HUEMOELLER IIExecutive Officer, Director
- Offering amount
- $5M
- Amount sold
- $500K
- Minimum investment
- $100
- First sale
- Jun 2020
- Incorporated
- Corporation, Nevada, 2018
- Federal exemptions
- 06b
▶$600KraisedMay 2018 · 1 investors · BiotechnologyRule 506(b)
- John W Huemoeller IIDirector
- LeKhram ChangoerExecutive Officer, Director
- Robert MalasekExecutive Officer
- George AnatassovExecutive Officer, Director
- Blake N SchroederDirector
- Robert CunninghamDirector
- Philip Van DammeExecutive Officer, Director
- Timothy R ScottDirector
- Offering amount
- $600K
- Amount sold
- $600K
- Minimum investment
- $600K
- First sale
- May 2018
- Incorporated
- Corporation, Nevada, 2018
- Federal exemptions
- 06b
▶Undisclosed amountofferedOct 2014 · OtherRule 506(b)
- Dr. Philip A Van DammeExecutive Officer, Director
- Dr. George AnastassovExecutive Officer, Director
- Lekhram ChangoerExecutive Officer, Director
- Incorporated
- Corporation, Nevada, 2010
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Axim Biotechnologies do?
- AXIM Biotechnologies is a research and development company that develops rapid point-of-care diagnostic tests for ophthalmological conditions, targeting ocular biomarkers linked to aqueous deficient dry eye disease and allergic conjunctivitis. Its tests are designed to help eye-care physicians detect and quantify these biomarkers.
- Who founded Axim Biotechnologies?
- Axim Biotechnologies was founded by Dr. Philip A Van Damme, Dr. George Anastassov, Catalina Valencia in 2018.
- How much funding has Axim Biotechnologies raised?
- Axim Biotechnologies has disclosed $1.2M raised across 3 of its 4 known rounds.
- Where is Axim Biotechnologies headquartered?
- Axim Biotechnologies is headquartered in New York, US.